Bio-Techne Corporation (NASDAQ: TECH) announced a licensing agreement with Monod Bio for exclusive commercial rights to a subset of NovoBody™ Duo molecules, AI-designed bispecific binding proteins.
The agreement grants Bio-Techne access to molecules developed by the Seattle-based biotechnology company, which spun out from Nobel Prize-winner David Baker's lab at the University of Washington's Institute for Protein Design.
NovoBody™ Duo molecules are designed to offer multi-specific binding capabilities for research and diagnostic applications. According to the companies, these proteins can be engineered more quickly and cost-effectively than traditional antibodies.
"This partnership marks an exciting step forward in how we are using artificial intelligence to advance scientific progress," said Will Geist, President of the Protein Sciences Segment at Bio-Techne. "NovoBody™ Duo molecules extend our portfolio with innovative AI-powered designs and state-of-the-art customization, stability, and performance."
Alfredo Quijano Rubio, Chief Science Officer of Monod Bio, stated that the molecules are "compact, tunable, and rapidly adaptable for multi-specific binding applications."
Bio-Techne generated over $1.2 billion in net sales in fiscal 2025 and employs approximately 3,100 people worldwide. The Minneapolis-based company provides life science tools, reagents and diagnostic products globally.
Monod Bio operates under a "Monod Inside" business model, partnering with research and diagnostic organizations to commercialize protein-based products. The company uses AI-powered protein design to create novel protein binders and biosensors for research and diagnostic applications.